Strontium ranelate (Protelos), a strontium (II) salt of ranelic acid, is an agent for the treatment of osteoarthritis and osteoporosis. Classified as a dual-action bone agent (DABA), strontium ranelate is unique in that it can simultaneously inhibit bone resorption and stimulate bone formation. [1]
More specifically, strontium ranelate increases in vitro osteoblast differentiation from progenitors, as well as osteoblast-induced osteoclastogenesis both in vitro and in vivo. Regarding bone-antiresorbing mechanisms, strontium ranelate decreases osteoclast differentiation and activity, while increasing their apoptosis. [2]
Technical information:
| Chemical Formula: | C12H6N2O8SSr2 | |
| CAS #: | 135459-87-9 | |
| Molecular Weight: | 513.49 | |
| Purity: | >98% | |
| Appearance: | White | |
| Chemical Name: | 5-[Bis(carboxymethyl)amino]-2-carboxy-4-cyano-3-thiopheneacetic Acid Strontium Salt | |
| Solubility: | Up to 22 mM in DMSO | |
| Synonyms: | Strontium ranelate, Protelos, Osseor, Ranelic acid distrontium salt |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Ireland, G., Protos: The first dual-action bone agent for osteoporosis, JEMDSA, 2006, 11(1), 35. |
| 2. | Fonseca et al., Mechanism of action of strontium ranelate: what are the facts? Clin. Cases. Mineral Bone Metabol. 2010, 7(1), 17-18. Pubmed ID: 22461285 |
Other Information:
Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.
